Hilco Streambank is actively seeking offers to acquire the intellectual property assets of the UK-based biotech company, Biosignatures Ltd (in Liquidation).
Steven Ross and Allan Kelly, of FRP Advisory Trading Limited, as Joint Liquidators of Biosignatures Ltd (in Liquidation) (“Biosignatures” or the “Company”) have appointed Hilco Streambank to seek interested parties with regards to the Company’s intellectual property assets.
Biosignatures was an AI Cloud software company supporting advanced blood sample analysis for use within healthcare ecosystems. The Company was developing a proprietary platform aimed at providing health insights for multiple conditions from a single drop of blood.
The Company’s platform is based on systematically improved workflows and algorithms for 2D-Gel Electrophoresis and the adaptation of this technique for consistency within large populations. The platform offers highly sensitive analysis of whole protein post-translational modification patterns and the ability to multiplex assays for simultaneous detection of multiple biomarkers from a single patient sample.
Having spent 12 years and in the region of £10m developing and refining its solution, Biosignature’s platform has been used in clinical studies, successfully identifying a biomarker for prostate cancer which is currently undergoing validation in clinical trials. In addition, it has identified several other potential biomarkers related to Alzheimer’s Disease and cancer.
This unique opportunity would allow a trade party or life science investor to acquire the intellectual property assets underpinning this near-market analytics platform.
The Company was developing a cloud-based software platform for sensitive analysis of protein biomarkers.
The platform is currently optimised to provide a customer interface that incorporates auditable quality control, statistical process control, billing, and security, and to apply the Biosignatures algorithms to 2D gel data.
It is designed to integrate with a lab-based piece of software that performs basic data quality control and metadata entry, subsequently performing complex analysis via external processing to get from raw data (2D gel images) to a set of measurements. It then uses a second external application to advance from measurements to an end-user (clinician or home user) report.
The Company holds rights in two Granted US patents (US Patent 7747049; US Patent 7747048) which relate to methods of applying statistical analysis to protein separation patterns.
The Company holds various data, documentation, and know-how (e.g. Lab SOPs, Lab notebooks) supporting the application of its workflows and analytical processing methods.
The Company holds rights in a sample bank of 2,589 patient samples collated from clinical studies in which the platform has been used.
Website & Domain Name
The Company holds rights in a bespoke website and domain name, located at biosignatures.com, which provides further detail on the Company’s aims and technology.
All expressions of interest and bids are to be directed to Hilco Streambank in writing. A Bid Submission Form is available on request. Please contact Hilco Streambank to gain access to a virtual data room of further information on signing of a confidentiality agreement.
The Joint Liquidators acts as agents of the Company and without personal liability.
The bidder acknowledges that Hilco acts as an agent for the Joint Liquidators of the Company who offers for sale only what right, title and interest (if any) the Company possesses in the assets. Such sale will be without any warranties, expressed or implied. Neither Hilco nor the Joint Liquidators have verified the information provided, and bidders are deemed to have carried out their own due diligence.
VAT, if applicable, at 20% will be added to the price. A buyer’s premium of 10% applies to this sale. A non-refundable deposit of 20% will be payable by the buyer within 48 hours of bid acceptance. Legal completion to occur within 5 business days of bid acceptance. Hilco Streambank’s full Terms & Conditions apply.